title: Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
abstract: Epstein-Barr virus (EBV) is constantly present in undifferentiated and poorly-differentiated nasopharyngeal cancer. Thus, tumour-associated viral antigens are potential targets for immunotherapy. Recently, both preclinical and early clinical studies have shown that various strategies can enhance EBV-specific immunity. Moreover, significant anti-tumour effect has been observed, and was generally correlated with biological response. The present review discusses the rational for EBV-targeted immunotherapy and summarises the latest developments in this area.
authors.affiliation: Department of Medical Oncology, Habib Bourguiba Hospital, Sfax 3029, Tunisia. masmoudi33@yahoo.fr
authors.forename: Amine
authors.initials: A
authors.lastname: Masmoudi
authors.forename: Nabil
authors.initials: N
authors.lastname: Toumi
authors.forename: Afef
authors.initials: A
authors.lastname: Khanfir
authors.forename: Lamia
authors.initials: L
authors.lastname: Kallel-Slimi
authors.forename: Jamel
authors.initials: J
authors.lastname: Daoud
authors.forename: Hela
authors.initials: H
authors.lastname: Karray
authors.forename: Mounir
authors.initials: M
authors.lastname: Frikha
mesh_terms: D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology / Q000628:therapy*; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D007167:Immunotherapy; D009303:Nasopharyngeal Neoplasms / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology